{"id":20264,"date":"2021-07-28T11:50:40","date_gmt":"2021-07-28T11:50:40","guid":{"rendered":"https:\/\/www.mymsd.ch\/fr\/?page_id=20264"},"modified":"2025-05-22T13:13:42","modified_gmt":"2025-05-22T13:13:42","slug":"best-treatment-first","status":"publish","type":"page","link":"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/","title":{"rendered":"Best treatment first"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1500\" height=\"611\" src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png\" alt=\"\" class=\"wp-image-18491\" srcset=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png 1500w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png?resize=300,122 300w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png?resize=768,313 768w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png?resize=1024,417 1024w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png?resize=320,130 320w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png?resize=120,49 120w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png?resize=1400,570 1400w\" sizes=\"auto, (max-width: 1500px) 100vw, 1500px\" \/><\/figure>\n\n\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\" id=\"backtop\"><img loading=\"lazy\" decoding=\"async\" width=\"572\" height=\"265\" src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_57_fr.png\" alt=\"\" class=\"wp-image-18492\" srcset=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_57_fr.png 572w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_57_fr.png?resize=300,139 300w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_57_fr.png?resize=320,148 320w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_57_fr.png?resize=120,56 120w\" sizes=\"auto, (max-width: 572px) 100vw, 572px\" \/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"572\" height=\"265\" src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_half_fr.png\" alt=\"\" class=\"wp-image-18493\" srcset=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_half_fr.png 572w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_half_fr.png?resize=300,139 300w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_half_fr.png?resize=320,148 320w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_half_fr.png?resize=120,56 120w\" sizes=\"auto, (max-width: 572px) 100vw, 572px\" \/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n\n\n<h2 class=\"wp-block-heading mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--71e90308383e57616574023df1620462\"><strong><strong>LES IMMUNOTH\u00c9RAPIES SONT EN TRAIN DE MODIFIER LE PARADIGME DE TRAITEMENT POUR LES PATIENTS \u00c0 UN STADE AVANC\u00c9 DE CBNPC<\/strong><\/strong><\/h2>\n\n\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<p class=\"has-text-align-justify mhh-mcn-v1-paragraph--justify  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--90816e8b820b119f5e8563079034b969\">L\u2019association d\u2019immunoth\u00e9rapies cibl\u00e9es \u00e0 une chimioth\u00e9rapie a montr\u00e9 de meilleurs r\u00e9sultats d\u2019OS et de PFS que la chimioth\u00e9rapie seule<sup>5<\/sup>, avec des \u00e9tudes sugg\u00e9rant que la combinaison d\u2019inhibiteurs du point de contr\u00f4le immunitaire et d\u2019une chimioth\u00e9rapie doit \u00eatre consid\u00e9r\u00e9e comme la&nbsp;<strong>nouvelle norme de soins<\/strong>&nbsp;pour les patients atteints de CBNPC m\u00e9tastatique de type sauvage.<sup>6,7<\/sup><\/p>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"520\" height=\"232\" src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_charts_fr.png\" alt=\"\" class=\"wp-image-18494\" srcset=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_charts_fr.png 520w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_charts_fr.png?resize=300,134 300w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_charts_fr.png?resize=320,143 320w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/07\/campaign_BTF_charts_fr.png?resize=120,54 120w\" sizes=\"auto, (max-width: 520px) 100vw, 520px\" \/><figcaption class=\"wp-element-caption\">M\u00e9ta-analyse de 8 essais (n = 4 646) chez des patients \u00e0 un stade avanc\u00e9 de CBNPC squameux (29 %) et non-squameux (71 %), r\u00e9alis\u00e9e en octobre 2018. Les patients ont \u00e9t\u00e9 randomis\u00e9s pour recevoir une chimioth\u00e9rapie de premi\u00e8re ligne plus un inhibiteur du point de contr\u00f4le anti PD-1 ou anti PD-L1 par rapport \u00e0 une chimioth\u00e9rapie de premi\u00e8re ligne.<sup>5<\/sup><\/figcaption><\/figure>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n\n\n<section class=\"wp-block-mconnect-theme-section has-light-grey-background-color has-background sub__entry__content wp-block-mconnect-theme-section--align-full has-red-border-color\">\n\t<div class=\"mhh-mcn-container\">\n\t\t\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/players.brightcove.net\/1905768940001\/meAxH3mZK_default\/index.html?videoId=6150234385001\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"571\" height=\"349\" src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/campaign_BTF_vid_image.png\" alt=\"\" class=\"wp-image-26390\" srcset=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/campaign_BTF_vid_image.png 571w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/campaign_BTF_vid_image.png?resize=300,183 300w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/campaign_BTF_vid_image.png?resize=320,196 320w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/campaign_BTF_vid_image.png?resize=120,73 120w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/campaign_BTF_vid_image.png?resize=130,80 130w\" sizes=\"auto, (max-width: 571px) 100vw, 571px\" \/><\/a><\/figure>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image alignleft size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"603\" height=\"187\" src=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/cappuzzo_fr.png\" alt=\"\" class=\"wp-image-26848\" srcset=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/cappuzzo_fr.png 603w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/cappuzzo_fr.png?resize=300,93 300w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/cappuzzo_fr.png?resize=320,99 320w, https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/09\/cappuzzo_fr.png?resize=120,37 120w\" sizes=\"auto, (max-width: 603px) 100vw, 603px\" \/><\/figure>\n\n\n\n<p class=\"   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--58863f7279c93a6b26e4e8eb03e91b6d\">Le Dr Cappuzzo, directeur du service d&rsquo;oncologie et d&rsquo;h\u00e9matologie, AUSL della Romagna-Ravenna, Italie, envisage d&rsquo;utiliser un traitement plus efficace en premi\u00e8re ligne, et sugg\u00e8re que cela est important, particuli\u00e8rement pour les patients atteints d&rsquo;un cancer du poumon, car nous n&rsquo;avons pas la certitude que le patient atteindra une deuxi\u00e8me ligne de traitement.<\/p>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n    <\/div>\n<\/section>\n\n\n\n<div class=\"wp-block-buttons is-vertical is-layout-flex wp-container-core-buttons-is-layout-8cf370e7 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-primary\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first-keytruda\/#keytruda-banner\">CONNECTEZ-VOUS POUR<br>PLUS D&rsquo;INFORMATIONS<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\" \/>\n\n\n\n<h5 class=\"wp-block-heading  mhh-mcn-v1-heading mhh-mcn-v1-heading--d8d44e3df5b79d21865af5673be8682a\"><span class=\"has-inline-color has-grey-color\"><strong><em>Notes de bas de page<\/em><\/strong><\/span><\/h5>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--89ab19ae8169b4622f8ec3aaba551aa4\"><span class=\"has-inline-color has-grey-color\"><em><sup>*<\/sup>Les patients recevant un traitement de deuxi\u00e8me ligne apr\u00e8s le traitement de premi\u00e8re ligne \u00e0 base de platine pour un cancer&nbsp;bronchopulmonaire \u00ab non \u00e0 petites cellules \u00bb de stade IIIB\/IV r\u00e9cemment diagnostiqu\u00e9 lors de la p\u00e9riode pr\u00e9c\u00e9dant l&rsquo;immunoth\u00e9rapie (2007&nbsp;\u00e0 mi-2013).1 Une nette h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 a \u00e9t\u00e9 not\u00e9e entre les essais. Dans le groupe PDL1 bas (1-49), une nette h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 (p = 0,06)&nbsp;a \u00e9t\u00e9 not\u00e9e entre le type de m\u00e9dicament et l&rsquo;efficacit\u00e9 : la combinaison de la chimioth\u00e9rapie et du pembrolizumab a offert un avantage en&nbsp;termes d&rsquo;OS (HR, 0,56 ; IC 95 %, 0,40-0,78 ; P&lt;0,00007) contrairement aux essais fondamentaux de l&rsquo;at\u00e9zolizumab (HR, 0,92 ; IC 95 %,&nbsp;0,62-1,37 ; P&lt;0,69).&nbsp;<sup>\u00a7<\/sup>&nbsp;Les p-valeurs \u00e9taient bilat\u00e9rales et nominales.<\/em><\/span><\/p>\n\n\n\n<h5 class=\"wp-block-heading  mhh-mcn-v1-heading mhh-mcn-v1-heading--1e75829e403c2c055c41b1a187429645\"><span class=\"has-inline-color has-grey-color\"><strong><em>Abr\u00e9viations<\/em><\/strong><\/span><\/h5>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--76ca5f58e23896e772493c08713bba4a\"><span class=\"has-inline-color has-grey-color\"><em>EI : \u00e9v\u00e9nement ind\u00e9sirable ; ALK : kinase du lymphome anaplasique ; BICR : blinded independent central review (examen central ind\u00e9pendant&nbsp;en aveugle) ; IC : intervalle de confiance ; EGFR : r\u00e9cepteur du facteur de croissance \u00e9pidermique ; HR : rapport de risque ; QVLS : qualit\u00e9&nbsp;de vie li\u00e9e \u00e0 la sant\u00e9 ; LS: moyenne des moindres carr\u00e9s apr\u00e8s QVLS ; NA : non atteint ; NCCN : National Comprehensive Cancer Network ;&nbsp;CBNPC : cancer bronchopulmonaire \u00ab non \u00e0 petites cellules \u00bb ; ORR : taux de r\u00e9ponse globale ; OS : survie globale ; PD-L1 : ligand de mort&nbsp;cellulaire programm\u00e9e de type 1 ; PFS : survie sans progression ; toutes les 3 sem. : toutes les 3 semaines ; QdV : qualit\u00e9 de vie.<\/em><\/span><\/p>\n\n\n\n<h5 class=\"wp-block-heading  mhh-mcn-v1-heading mhh-mcn-v1-heading--e5d6c5740e124d41c3480ec5dfc15f96\"><span class=\"has-inline-color has-grey-color\"><strong><em>R\u00e9f\u00e9rences<\/em><\/strong><\/span><\/h5>\n\n\n\n<ol class=\"wp-block-list has-negative-1-font-size\">\n<li><em><span class=\"has-inline-color has-grey-color\">Arunachalam A, et al. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018;19:e783-e799.<\/span><\/em><\/li>\n\n\n\n<li><em><span class=\"has-inline-color has-grey-color\">Gadgeel S, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer [publication en ligne avant la publication papier le 9 mars 2020]. J Clin Oncol. doi:10.1200\/JC0.19.03136.<\/span><\/em><\/li>\n\n\n\n<li><em><span class=\"has-inline-color has-grey-color\">Paz-Ares L, et al. Pembrolizumab Plus Chemotherapy in Metastatic Squamous NSCLC: Final Analysis and Progression After the Next Line of Therapy (PFS2) in KEYNOTE-407. Affiche LBA852, pr\u00e9sent\u00e9e au Congr\u00e8s de l\u2019European Society for Medical Oncology (ESMO); 27 septembre &#8211; 1er octobre 2019 ; Barcelone, Espagne.<\/span><\/em><\/li>\n\n\n\n<li><span class=\"has-inline-color has-grey-color\"><em>National Cancer Institute. Cancer Stat Facts: Lunch and Bronchus Cancer, 2020.<br>Disponible \u00e0 l&rsquo;adresse suivante : https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html Consult\u00e9 en avril 2020.<\/em><\/span><\/li>\n\n\n\n<li><em><span class=\"has-inline-color has-grey-color\">Addeo A, et al. Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. Front Oncol. 2019 16;9:264.<\/span><\/em><\/li>\n\n\n\n<li><em><span class=\"has-inline-color has-grey-color\">Planchard D, et al. Metastatic Non-small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology 29(supplement 4): iv192-iv237, 2018.<\/span><\/em><\/li>\n\n\n\n<li><em><span class=\"has-inline-color has-grey-color\">NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer. NCCN Evidence Block<sup>\u2122<\/sup>. Version 1.2020. \u00a9 National Comprehensive Cancer Network, Inc. 2019. Tous droits r\u00e9serv\u00e9s. Consult\u00e9 en avril 2020. Pour consulter la version la plus r\u00e9cente et la plus compl\u00e8te des lignes directrices, acc\u00e9dez en ligne \u00e0 NCCN.org.<\/span><\/em><\/li>\n\n\n\n<li><em><span class=\"has-inline-color has-grey-color\">Garassino M, et al. Patient-reported Outcomes Following Pembrolizumab or Placebo Plus Pemetrexed and Platinum in Patients With Previously Untreated, Metastatic, Non-Squamous Non-Small-Cell Lung Cancer (KEYNOTE-189): A Multi Centre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Oncol. 2020 21(3):387-397.<\/span><\/em><\/li>\n\n\n\n<li><em><span class=\"has-inline-color has-grey-color\">Mazieres J, et al. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 Jan 20;38(3):271-280.<\/span><\/em><\/li>\n\n\n\n<li><em><span class=\"has-inline-color has-grey-color\">Gandhi L, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378:2078-2092.<\/span><\/em><\/li>\n\n\n\n<li><span class=\"has-inline-color has-grey-color\"><em>Paz-Ares L, et al; Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Eng J Med 2018;379:2040-2051.<\/em><\/span><\/li>\n<\/ol>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--37b0c910e222aa3167ef24411aa34118\"><span class=\"has-inline-color has-grey-color\"><em>Avant de prescrire, veuillez consulter les informations de prescription compl\u00e8tes publi\u00e9es sur la page d\u2019accueil de Swissmedic (<a href=\"https:\/\/www.swissmedicinfo.ch\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo.ch<\/a>).<\/em><\/span><\/p>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7844472b808040ac86896016a884e742\"><span class=\"has-inline-color has-grey-color\"><em>Des copies des publications de l\u2019\u00e9tude peuvent \u00eatre demand\u00e9es \u00e0 l\u2019adresse ci-dessous.\u00a9 MSD Merck Sharp &amp; Dohme AG, Werftestrasse 4, 6005 Lucerne, Suisse. Tous droits r\u00e9serv\u00e9s. <a href=\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/keytruda\/\">Cliquez ici pour obtenir les informations de prescription de KEYTRUDA\u00ae (Pembrolizumab).<\/a><\/em><\/span><\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--de28d055a4b5fb1bc548d6e7d315f50d\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--268d84aeaf8460d656adf59658826334 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"\/fr\/succinctstatement\/keytruda\/\" target=\"_self\" aria-label=\"Information professionnelle abr\u00e9g\u00e9e de KEYTRUDA\u00ae\">\n                    <span class=\"mhh-mcn-v1-link__label\">Information professionnelle abr\u00e9g\u00e9e de KEYTRUDA\u00ae<\/span>\n                <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LES IMMUNOTH\u00c9RAPIES SONT EN TRAIN DE MODIFIER LE PARADIGME DE TRAITEMENT POUR LES PATIENTS \u00c0 UN STADE AVANC\u00c9 DE CBNPC [&hellip;]<\/p>\n","protected":false},"author":164,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":true,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","primary_tag":0,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["active","is_keyword","is_date"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[729],"tags":[],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[957],"ga4_page_businessunit":[963],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[1206],"ga4_page_product":[],"ga4_page_region":[],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[627],"tx-product":[642],"tx-pathology":[],"tx-content-type":[682],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-20264","page","type-page","status-publish","hentry","category-campaigns"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Best treatment first - MyMSD.ch FR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Best treatment first - MyMSD.ch FR\" \/>\n<meta property=\"og:description\" content=\"LES IMMUNOTH\u00c9RAPIES SONT EN TRAIN DE MODIFIER LE PARADIGME DE TRAITEMENT POUR LES PATIENTS \u00c0 UN STADE AVANC\u00c9 DE CBNPC [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch FR\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-22T13:13:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/\",\"name\":\"Best treatment first - MyMSD.ch FR\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png\",\"datePublished\":\"2021-07-28T11:50:40+00:00\",\"dateModified\":\"2025-05-22T13:13:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/#primaryimage\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png\",\"width\":1500,\"height\":611},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Best treatment first\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"name\":\"MyMSD.ch FR\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"width\":4084,\"height\":692,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Best treatment first - MyMSD.ch FR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/","og_locale":"fr_FR","og_type":"article","og_title":"Best treatment first - MyMSD.ch FR","og_description":"LES IMMUNOTH\u00c9RAPIES SONT EN TRAIN DE MODIFIER LE PARADIGME DE TRAITEMENT POUR LES PATIENTS \u00c0 UN STADE AVANC\u00c9 DE CBNPC [&hellip;]","og_url":"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/","og_site_name":"MyMSD.ch FR","article_modified_time":"2025-05-22T13:13:42+00:00","og_image":[{"url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/","url":"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/","name":"Best treatment first - MyMSD.ch FR","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/#primaryimage"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png","datePublished":"2021-07-28T11:50:40+00:00","dateModified":"2025-05-22T13:13:42+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/#primaryimage","url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png","contentUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2021\/06\/banner_campaign_BTF_fr.png","width":1500,"height":611},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/fr\/best-treatment-first\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Best treatment first"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/fr\/#website","url":"https:\/\/www.mymsd.ch\/fr\/","name":"MyMSD.ch FR","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/fr\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","contentUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","width":4084,"height":692,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/20264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/users\/164"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/comments?post=20264"}],"version-history":[{"count":16,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/20264\/revisions"}],"predecessor-version":[{"id":100326,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/20264\/revisions\/100326"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/media?parent=20264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/categories?post=20264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tags?post=20264"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_audience?post=20264"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_birn_id?post=20264"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_branding?post=20264"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_businessunit?post=20264"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_campaign?post=20264"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=20264"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=20264"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=20264"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_experience?post=20264"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_indication?post=20264"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_material_intent?post=20264"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_product?post=20264"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_region?post=20264"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=20264"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-therapeutic-area?post=20264"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-product?post=20264"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-pathology?post=20264"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-content-type?post=20264"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-active-ingredient?post=20264"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/access?post=20264"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_status?post=20264"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_role?post=20264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}